RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Add to Collection
2010 Aug 7 Others Fist_Author_Year_PM

Full Author : ['Bergenstal, Richard M', 'Wysham, Carol', 'Macconell, Leigh', 'Malloy, Jaret', 'Walsh, Brandon', 'Yan, Ping', 'Wilhelm, Ken', 'Malone, Jim', 'Porter, Lisa E']
Journal Title : Lancet (London, England)
Chapter : Section3
Journal Year : 2010
Cited by : Not Available

BACKGROUND: Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approve.....

Keywords : ["weekly versus sitagliptin", "type diabetes", "randomised trial", "treatment", "safety", "pioglitazone", "metformin", "exenatide", "efficacy", "adjunct"]